A groundbreaking development is set to unfold in England, as a life-prolonging medication for prostate cancer will soon be accessible to thousands of men. This pivotal change comes after relentless advocacy from patients and charitable organizations.
Abiraterone, a drug already available through the NHS in Scotland and Wales since 2023, will now be offered to men in England—marking a significant shift in treatment availability, particularly for those in high-risk categories whose cancer has not yet spread. Previously, this medication was reserved for only the most severe cases in England and Northern Ireland, leaving many without crucial support.
The introduction of abiraterone represents a potential turning point for countless men battling prostate cancer, with estimates suggesting that around 7,000 individuals annually will begin this treatment. Furthermore, it's anticipated that approximately 1,470 men will avoid the distressing news that their condition has worsened, possibly saving about 560 lives.
Amy Rylance, who serves as the assistant director of health improvement at Prostate Cancer UK, expressed her elation, stating that this decision marks a "momentous, life-saving victory" for many. She commended the BBC for maintaining a spotlight on this issue through consistent coverage over recent years, which played a key role in raising awareness (source: https://www.bbc.co.uk/news/health-67065504).
NHS England has confirmed that this vital medication will be available within weeks. Approximately 2,000 men diagnosed with prostate cancer in the last quarter may receive abiraterone if it proves clinically beneficial.
So, how does this drug work? Abiraterone functions by inhibiting the production of hormones that fuel cancer growth, effectively starving the disease and preventing its spread. For example, Giles Turner, a patient from Brighton diagnosed with aggressive prostate cancer in March 2023, initially sought out the drug after learning he could access it in Scotland and Wales but not in his home country. He voiced his frustration, stating, "I was shocked and angered that my postcode meant I was denied free access to a treatment that could halve my risk of dying and give me the best chance of a cure." His determination led him to pay out of pocket for the medication, costing him £250 monthly, while advocating for policy changes to ensure others would not face similar barriers.
Initially, NHS England indicated they were reviewing the broader application of abiraterone for more patients. However, when Prostate Cancer UK followed up, officials stated there were no funds available, a message echoed by ministers in early 2025. Mr. Turner remarked, "Today's wonderful news is the culmination of all our determined and dogged efforts," expressing his happiness that equitable access to this effective treatment could save many lives and spare families from heartbreak, albeit with frustration over the prolonged timeline.
The foundation for Prostate Cancer UK's assertions regarding the drug's life-saving potential lies in findings from the STAMPEDE trial, published in 2022, which demonstrated enhanced survival rates among men receiving abiraterone alongside standard care. According to the Institute of Cancer Research, a two-year treatment with abiraterone can reduce the likelihood of cancer recurrence by half and lower the death rate by 40%.
Despite these promising outcomes, there had been significant disappointment when the National Institute for Health and Care Excellence (NICE), the health watchdog, did not approve the drug's use for newly diagnosed patients. The process for extending a drug's usage involves intricate and lengthy applications, which can deter companies from pursuing approvals once the drug goes off patent. Following October 2022, when abiraterone lost its patent protection, it became a generic medicine, allowing other firms to sell it; however, this also diminished the motivation for new approvals for expanded patient use.
In contrast, health authorities in Scotland and Wales successfully navigated existing protocols to provide the drug through the NHS. Unfortunately, similar advancements did not occur in England until now, with NHS England announcing that savings from other medications have finally allowed for an expansion of abiraterone's availability.
Professor Peter Johnson, the national clinical director for cancer at NHS England, emphasized that this life-extending treatment will soon be available to thousands, allowing them to embark on a new year with hope for longer, healthier lives. Health and Social Care Secretary Wes Streeting added, "When you're living with prostate cancer, every day with your loved ones matters. I'm delighted the NHS has taken the steps needed to make the drug available, giving thousands of men access to abiraterone—a treatment that significantly improves survival rates and can grant patients precious extra years of life."
In a heartfelt response to the announcement, Professor Gert Attard, co-lead of the STAMPEDE trial at the UCL Cancer Institute, remarked, "This is a hugely welcome moment for patients. Our research showed clearly that abiraterone can save lives when offered earlier to men at high risk of their cancer spreading."
Prostate Cancer UK is now actively engaging with decision-makers in Northern Ireland to advocate for similar access to the medication, urging political leaders in Stormont to expedite changes in prescription practices. As of now, Stormont has yet to clarify any intentions regarding adjustments in the availability of abiraterone.
